Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
Teva Pharmaceutical Industries Limited furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the period ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The company states the information is being furnished, not filed, under the Exchange Act, which means it is not subject to Section 18 liability, unless specifically incorporated by reference elsewhere.
Harel Insurance Investments & Financial Services Ltd. reported ownership of 58,118,222 ordinary shares of Teva Pharmaceutical Industries Ltd, representing 5.1% of the class based on 1,147,150,917 shares outstanding as of June 30, 2025. Most shares are held on behalf of public clients: 56,881,124 for pooled public funds, 114,084 in third-party client accounts (with no voting power), and 1,123,014 beneficially held for Harel's own account. The filing shows shared voting power of 58,004,138 and shared dispositive power of 58,118,222. The statement clarifies these holdings are not intended to affect control of the issuer and discloses Israeli organization and office addresses.
David R. McAvoy, identified as an Executive Vice President and Chief Legal Officer of Teva Pharmaceutical Industries Ltd. (TEVA), reported an open-market purchase of 1,113 ordinary shares on 09/05/2025 at a price of $18.8572 per share. After the transaction McAvoy beneficially owns 13,027 ordinary shares. The filing notes that the ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
The Form 4 was signed on behalf of McAvoy by an attorney-in-fact and filed under Section 16 reporting requirements. The report contains no other derivative transactions or additional disclosures.